Clinical trial
Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast…
NCT00006104 · Vanderbilt-Ingram Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006104 |
|---|---|
| Title | Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer |
| Official title | A Multi-Institutional Phase II Pilot Trial With Weekly Docetaxel and Herceptin as First or Second Line Therapy for HER2/Neu Overexpressing Metastatic Breast Cancer |
| Lead sponsor | Vanderbilt-Ingram Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, docetaxel |
| Enrollment | 46 |
| Start date | Sep 1, 1998 |
| Primary completion | Jul 1, 2003 |
| Completion | Jul 1, 2003 |
| First posted | Dec 24, 2003 |
| Last update posted | Aug 14, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: